Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine (medicinal product) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine in oral dose form (medicinal product form) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Caffeine |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Bronchodilator (substance) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Stimulant (substance) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Xanthine |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing paracetamol (medicinal product) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing dihydrocodeine (medicinal product) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Paracetamol |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dihydrocodeine bitartrate |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Non-opioid analgesic (substance) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dihydrocodeine (substance) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine and dihydrocodeine tartrate and paracetamol |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Opioid receptor agonist |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Phosphodiesterase inhibitor |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has manufactured dose form |
A solid single-dose form that is a shell made of gelatin or other substances. The contents of the shell may be a solid, semi-solid or liquid. |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Xanthine |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dihydrocodeine tartrate |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine in oral dose form (medicinal product form) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has manufactured dose form |
Oral capsule |
true |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing paracetamol in oral dose form (medicinal product form) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Dihydrocodeine tartrate |
false |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
16 |
false |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute specifies the numerator unit for the presentation strength of a product. |
mg |
true |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator value |
un |
false |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute specifies the denominator unit for the presentation strength of a product. |
Capsule (unit of presentation) |
true |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute specifies the numerator unit for the presentation strength of a product. |
mg |
true |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator value |
un |
false |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute specifies the denominator unit for the presentation strength of a product. |
Capsule (unit of presentation) |
true |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute specifies the numerator unit for the presentation strength of a product. |
mg |
true |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength denominator value |
un |
false |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute specifies the denominator unit for the presentation strength of a product. |
Capsule (unit of presentation) |
true |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Paracetamol |
true |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
356.4 |
false |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Paracetamol |
false |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Paracetamol |
false |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
356.4 |
false |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Caffeine |
false |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Caffeine |
false |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
30 |
false |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dihydrocodeine tartrate |
false |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Dihydrocodeine tartrate |
false |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has presentation strength numerator value |
16 |
false |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Caffeine |
false |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Has unit of presentation |
Capsule (unit of presentation) |
true |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Dihydrocodeine tartrate |
false |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Paracetamol |
true |
Inferred relationship |
Some |
3 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing caffeine and dihydrocodeine and paracetamol in oral dose form (medicinal product form) |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Count of base of active ingredient |
trois |
false |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
Is a |
Product containing only caffeine and dihydrocodeine and paracetamol in oral dose form (medicinal product form) |
true |
Inferred relationship |
Some |
|
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Dihydrocodeine tartrate |
true |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Dihydrocodeine tartrate |
true |
Inferred relationship |
Some |
2 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
Caffeine |
true |
Inferred relationship |
Some |
1 |
|
Caffeine 30 mg and dihydrocodeine tartrate 16 mg and paracetamol 356.4 mg oral capsule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
Caffeine |
true |
Inferred relationship |
Some |
1 |
|